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Chronic antipsychotic treatment differentially modulates protein kinase A-
and glycogen synthase kinase 3 beta-dependent signaling pathways, N-
methyl-D-aspartate receptor and γ-aminobutyric acid A receptors in
nucleus accumbens of juvenile rats
Abstract
Background: Antipsychotics are developed to treat mental disorders in adults; however, the prescription
(mostly "off-label") of antipsychotics for children/adolescents has been constantly increasing over years. The
influences of antipsychotics on juveniles requires investigation to validate their clinic use. Antipsychotics
mainly exert their effects via several receptors and signaling pathways.
Aims: This study examined the effects of aripiprazole, olanzapine, and risperidone on selected signaling
pathways, N-methyl-D-aspartate, and γ-aminobutyric acid A receptors in juveniles.
Methods: Rats were orally administered aripiprazole (1 mg/kg), olanzapine (1 mg/kg), risperidone (0.3 mg/
kg), or vehicle three times/day from postnatal day 23 (±1 day) for three weeks. The effects of antipsychotics
in the nucleus accumbens and caudate putamen were measured by Western blots.
Results: In the nucleus accumbens, all three drugs differentially increased N-methyl-D-aspartate and γ-
aminobutyric acid A receptor expression. Additionally, all three antipsychotics differentially elevated the
phosphorylation of glycogen synthase kinase 3 beta, β-catenin, and cAMP-responsive element-binding
protein 1. In the caudate putamen, olanzapine increased β-catenin phosphorylation; and aripiprazole and
olanzapine elevated γ-aminobutyric acid A receptor levels. Correlation analysis indicated that antipsychotics
might modulate N-methyl-D-aspartate receptors via glycogen synthase kinase 3 beta-β-catenin signaling and/
or cAMP-responsive element-binding protein 1 activation.
Conclusions: These findings suggest that antipsychotics can affect protein kinase A- and glycogen synthase
kinase 3 beta-dependent signaling pathways in juveniles; and their modulation on N-methyl-D-aspartate and
γ-aminobutyric acid A receptors is probably through glycogen synthase kinase 3 beta-β-catenin signaling and/
or cAMP-responsive element-binding protein 1 activation.
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Background: Antipsychotics are developed to treat mental disorders in adults; however, 36 
the prescription (mostly “off-label”) of antipsychotics for children/adolescents has been 37 
constantly increasing over years. The influences of antipsychotics on juveniles requires 38 
investigation to validate their clinic use. Antipsychotics mainly exert their effects via 39 
several receptors and signalling pathways.  40 
Aims: This study examined the effects of aripiprazole, olanzapine, and risperidone on 41 
selected signalling pathways, N-methyl-D-aspartate, and γ-aminobutyric acid A receptors 42 
in juveniles.  43 
Methods: Rats were orally administered aripiprazole (1mg/kg), olanzapine (1mg/kg), 44 
risperidone (0.3mg/kg), or vehicle 3 times/day from postnatal day 23 (±1 day) for 3 45 
weeks. The effects of antipsychotics in the nucleus accumbens and caudate putamen were 46 
measured by Western Blots.  47 
Results: In the nucleus accumbens, all three drugs differentially increased N-methyl-D-48 
aspartate and γ-aminobutyric acid A receptor expression. Additionally, all three 49 
antipsychotics differentially elevated the phosphorylation of glycogen synthase kinase 3 50 
beta, β-catenin, and cAMP-responsive 51 
element-binding protein 1. In the caudate putamen, olanzapine increased β-catenin 52 
phosphorylation; and aripiprazole and olanzapine elevated γ-aminobutyric acid A 53 
receptor levels. Correlation analysis indicated that antipsychotics might modulate N-54 




and/or cAMP-responsive element-binding protein 1 activation.  56 
Conclusions: These findings suggest that antipsychotics can affect protein kinase A- and 57 
glycogen synthase kinase 3 beta -dependent signalling pathways in juveniles; and their 58 
modulation on N-methyl-D-aspartate and γ-aminobutyric acid A receptors is probably 59 
through glycogen synthase kinase 3 beta -β-catenin signalling and/or cAMP-responsive 60 
element-binding protein 1 activation. 61 
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Over the past decade, the prescription of antipsychotic drugs (mostly off-label use) in 71 
children and adolescents has increased markedly (Ronsley et al., 2013; Caccia, 2013). 72 
Particularly, risperidone (neuroscience-based nomenclature (NbN): dopamine D2, 73 
serotonin 5-HT2, noradrenaline NE α-2 receptor antagonist (Nutt and Blier, 2016)) is 74 
accounted for ~70% of total antipsychotic prescriptions (Olfson et al., 2010; Karanges et 75 
al., 2014). These antipsychotics are mostly prescribed to treat mental disorders, such as 76 
childhood-onset schizophrenia, depression, bipolar disorder, and autism (Schneider et al., 77 
2014). Clinical studies have shown that children/adolescents are more likely to be 78 
affected by antipsychotics than adults, especially by the side-effects (Vitiello et al., 2009). 79 
Since the pharmacodynamic sensitivity to antipsychotics in children/adolescents is 80 
different from that in adults (Caccia, 2013), understanding the pharmacological 81 
mechanisms of antipsychotics in children/adolescents is required and might provide 82 
important evidence for the prescription of antipsychotics for children/adolescents in 83 
clinics. 84 
Our previous evidence demonstrates that various antipsychotics influence G-protein 85 
dependent protein kinase A (PKA) signalling and G-protein independent protein kinase B 86 
(Akt)-glycogen synthase kinase 3 beta (GSK3β) signalling pathways to exert their effects 87 
in the striatum of adult animals (Pan et al., 2016b; Pan et al., 2016a; Pan et al., 2016c; 88 
Pan et al., 2015). However, to our knowledge, there is no study that investigates 89 
antipsychotic effects on these signalling pathways during the childhood-adolescent 90 
period. In addition, it has been widely accepted that antipsychotics are able to exert their 91 




dishevelled(Dvl)-GSK3β-β-catenin pathway has been reported to be modulated by 93 
various antipsychotics (including aripiprazole (NbN: dopamine D2, serotonin 5-HT1A 94 
receptor partial agonist (Nutt and Blier, 2016)), olanzapine (NbN: dopamine D2, 95 
serotonin 5-HT2 receptor antagonist (Nutt and Blier, 2016)), risperidone, etc.) in adults 96 
(Alimohamad et al., 2005b; Alimohamad et al., 2005a; Sutton and Rushlow, 2011; Seo et 97 
al., 2015; Pan et al., 2016a; Pan et al., 2016b). Antipsychotics (e.g. aripiprazole) might 98 
also exert therapeutic effects via cAMP-responsive element-binding protein 1 (CREB1) 99 
in adult animals (Mavrikaki et al., 2014; Pan et al., 2016c; Pan et al., 2016b). Whether 100 
these pathways and substrates are involved in the regulation of antipsychotics in 101 
children/adolescents is not clear. 102 
N-methyl-D-aspartate (NMDA) and GABAA(γ-aminobutyric acid) receptor signalling 103 
play key roles in neurodevelopment and the formation of brain core functions, and 104 
deficits in these receptors have been considered to be associated with various mental 105 
disorders in children/adolescents (Panaccione et al., 2013; Schmidt and Mirnics, 2015; 106 
Mouri et al., 2007; Sakamoto et al., 2011). Previous studies have shown that the GABAA 107 
receptor can be regulated by various antipsychotics in adults through dopamine D2 108 
receptor (D2R)-downstream PKA signalling, which was also suggested by our recent 109 
studies (Skilbeck et al., 2007; Zink et al., 2004; Pan et al., 2016c; Pan et al., 2016b); 110 
similarly, modulation of antipsychotics on NMDA receptors (NMDARs) in adults has 111 
also been well documented (Schmitt et al., 2003; Segnitz et al., 2011; Pan et al., 2016b); 112 
antipsychotics might regulate NMDARs via D2R-mediated GSK3β and CREB1 113 
signalling in adult rat brains (Pan et al., 2016b). Both NMDA and GABAA receptors are 114 




to be more sensitive to antipsychotic treatment (Fritschy et al., 1994; Lopez-Tellez et al., 116 
2004; Sheng et al., 1994). Although these antipsychotics target multiple receptors such as 117 
dopamine D2 and 5-HT2A receptors, D2Rs play a critical role in their therapeutic effects 118 
(Ginovart and Kapur, 2012). Both risperidone and aripiprazole have very high affinity 119 
with D2Rs (Correll, 2010). Unfortunately, there are very limited studies that have 120 
systematically examined the effects of early treatment with these antipsychotics on the 121 
D2R-mediated signalling pathways and substrates during childhood-adolescence, which is 122 
the key issue that needs to be addressed in the present study. Furthermore, the striatum, 123 
which mainly contains the nucleus accumbens (NAc) and caudate putamen (CPu), is a 124 
key brain region that is associated with the pathophysiology of various mental disorders 125 
in children/adolescents, such as schizophrenia, autism, depression, and bipolar disorder 126 
(DelBello et al., 2006; James et al., 2016; Langen et al., 2009; Gabbay et al., 2013). 127 
Therefore, in this study, we investigated the effects of oral treatment (3 times per day) of 128 
aripiprazole, olanzapine, and risperidone at a clinical equivalent dosage (a better 129 
mimicking of the clinical treatment paradigm) on the above mentioned PKA- and 130 
GSK3β-dependent signalling pathways as well as GABAA and NMDA receptors in the 131 
NAc and CPu of juvenile rats. 132 
Methods 133 
Animals and drug administration 134 
Fourteen timed, pregnant Sprague-Dawley rats were obtained at gestation day 14 from 135 
the Animal Resource Centre (Perth, WA, Australia). They were housed individually at 136 
22˚C, on a 12h light-dark cycle (lights on: 07:00 AM and light off: 7:00 PM), and 137 




experiment (Lian et al., 2016). To avoid variations from potential interactions with sexual 139 
hormones, twenty-four male pups born from these mother rats were used for this study. 140 
The day of birth was considered as postnatal day (PN) 0. On PN21, young male rats (n = 141 
6/group) were randomly assigned to one of the following treatments: aripiprazole (1.0 142 
mg/kg, t.i.d., Bristol-Myers Squibb, New York, USA), olanzapine (1.0 mg/kg, t.i.d., Eli 143 
Lilly, Indianapolis, IN, USA), risperidone (0.3 mg/kg, t.i.d., Apotex, Macquarie Park, 144 
NSW, Australia), or vehicle. Drug powders mixed with the cookie dough pellets was 145 
delivered orally 3 times per day at 07:00 AM, 03:00 PM and 11:00 PM (Pan et al., 2016b; 146 
Lian et al., 2016) from PN23 (±1 day). The treatment period was 3 weeks, which 147 
corresponds to childhood-adolescence in humans (Brenhouse and Andersen, 2011). 148 
Controls received equivalent pellets without drugs. All rats were sacrificed and the brains 149 
were obtained two hours after the final dose of antipsychotics. The brains were 150 
immediately frozen in liquid nitrogen and then stored under -80°C for future use. 151 
The rats were administered antipsychotic drugs three times/day to ensure consistently 152 
high concentrations to better mirror the human scenario of oral administration once per 153 
day (Lian et al., 2016; Pan et al., 2016b). The dosages were based on the recommended 154 
dosages in humans based on body surface area, according to the FDA guidelines for 155 
clinical trials (FDA, 2005; Reagan-Shaw et al., 2008), all of which are within the 156 
recommended dosage ranges for the psychiatric treatment of children/adolescents 157 
(Fraguas et al., 2011; Greenaway and Elbe, 2009). It has been previously reported that, at 158 
these used dosages, all these drug reaches 60-80% D2 receptor occupancy rates in the rat 159 
brain (Kapur et al., 2003; Natesan et al., 2006). All experimental procedures were 160 




complied with the Australian Code of Practice for the Care and Use of Animals for 162 
Scientific Purposes (National Health and Medical Research Council, Australia, 2004). 163 
Brain dissection 164 
The discrete brain regions were collected using a brain microdissection puncture 165 
technique as described previously (Pan et al., 2015; Pan et al., 2016c; Pan et al., 2016b). 166 
Specifically, based on the brain atlas (Paxinos and Watson, 2005), three sections through 167 
the striatum (Bregma 1.00 to 2.20mm) were dissected for the NAc and CPu, respectively. 168 
Dissected tissue was kept at -80°C for future use.  169 
Western blots 170 
Frozen brain samples were homogenised in homogenising buffer containing NP-40 cell 171 
lysis buffer (Invitrogen, #FNN0021), Protease Inhibitor Cocktail (Sigma-Aldrich, 172 
#P8340), β-Glycerophosphate (Sigma-Aldrich, #G9422), and PMSF (Sigma-Aldrich, 173 
#P7626). Protein concentration of each sample was measured by the DC Protein Assay 174 
(Bio-Rad, #500-0111). Western blot experiments were performed as described previously 175 
(Pan et al., 2016b; Pan et al., 2016a; Pan et al., 2016c). Briefly, each sample containing 176 
10µg of protein was denatured, and loaded into CriterionTM TGXTM Precast Gels (Bio-177 
rad, #5671095). The proteins were separated in CriterionTM Vertical Electrophoresis Cells 178 
(Bio-rad, #1656001), and then electrophoretically transferred to a polyvinylidene 179 
difluoride membrane in CriterionTM Blotters (Bio-rad, #1704071). All membranes were 180 
then blocked by 5% skim milk powder, and incubated in primary antibodies and 181 
secondary antibodies, respectively. The immunoreactive bands were visualised using 182 




Western HRP substrate (Millipore, #WBLUC0500). All Western blot experiments were 184 
performed in duplicate to ensure consistency.  185 
The following antibodies were used to detected corresponding proteins: anti-PKA-Cα 186 
(1:1000; Santa Cruz Biotechnology, #SC-903), anti-phosphor-PKA-C (Thr197) (1:1000; 187 
Cell Signaling Technology, #5661), anti-Akt (1:2000; Cell Signaling Technology, #4691), 188 
anti-phosphor-Akt (Thr308) (1:1000; Cell Signaling Technology, #13038), anti-GSK3β 189 
(1:2000; Cell Signaling Technology, #5676), anti-phospho-GSK3β (Ser9) (1:1000; Cell 190 
Signaling Technology, #9322), anti-Dvl-3 (1:1000; Santa Cruz Biotechnology, #SC-191 
8027), anti-β-catenin (1:1000; Santa Cruz Biotechnology, #SC-7963), anti-GABAA β-1 192 
(1:1000; Abcam, #ab154822), anti-CREB1 (1:2000, Abcam, #ab32515), and anti-193 
phospho-CREB1 (1:2000, Abcam, #ab32096). Mouse anti-actin primary polyclonal 194 
antibody (1:10000; Millipore, #MAB1501) was used to determine the actin levels. The 195 
secondary antibodies were HRP-conjugated anti-rabbit IgG antibody (1:3000; Cell 196 
Signaling Technology, #7074) and HRP-conjugated anti-mouse IgG antibody (1:3000; 197 
Cell Signaling Technology, #7076).  198 
Statistics 199 
The immunoreactive signals were quantified using Bio-Rad Image Lab (version 6.0). All 200 
data were analysed by using SPSS Statistics (version 24.0). The data of each targeted 201 
protein were then corrected based on their corresponding actin levels. Data normal 202 
distribution was tested using histograms and a Kolmogorov–Smirnov Z-test. One-way 203 
analysis of variance (ANOVA) was performed if the data were normally distributed, the 204 




group (using raw data). If the data were not normally distributed, the protein expression 206 
in each brain region was analysed by a Kruskal-Wallis H-test, followed by the post-hoc 207 
Mann–Whiney U-test. The results of each protein expression were expressed by taking 208 
the value of the control group as 100%. The ratios of each phosphorylated proteins were 209 
analysed by a Kruskal–Wallis H-test and the post-hoc Mann–Whiney U-test. Pearson’s 210 
correlation tests were employed to analyse the relationships among certain 211 
measurements. Statistical significance was accepted when p ≤ 0.05.  212 
Results 213 
The effect of antipsychotics on Akt and GSK3β 214 
In the NAc, antipsychotic administration did not exert any effects on Akt (Akt, F3, 20 = 215 
2.486, p > 0.05; p-Akt (Thr308), F3, 20 = 1.182, p > 0.05), whereas GSK3β was 216 
significantly affected by antipsychotic treatment (GSK3β, F3, 20 = 4.003, p < 0.05; p-217 
GSK3β, F3, 20 = 4.696, p > 0.05). Post-hoc tests have shown that risperidone down-218 
regulated the expression of GSK3β in the NAc by 64.0% (p < 0.05); in addition, both 219 
aripiprazole (p < 0.05) and olanzapine (p < 0.01) increased the expression of p-GSK3β 220 
(Ser9) by 59.4% and 90.0%, respectively (Figure 1(b), 1(d)). Furthermore, all three 221 
antipsychotics significantly elevated the ratio of p-GSK3β/GSK3β (aripiprazole, p < 222 
0.01; olanzapine, p < 0.05; risperidone, p < 0.01) (Figure 1(b)). 223 
In the CPu, on the other hand, the protein levels of Akt, p-Akt, GSK3β, and p-GSK3β 224 
were not significantly affected by any antipsychotic administration (Akt, F3, 20 = 0.910, p > 225 
0.05; p-Akt (Thr308), F3, 20 = 2.159, p > 0.05; GSK3β, F3, 20 = 1.671, p > 0.05; p-GSK3β 226 




GSK3β/GSK3β (both p > 0.05).  228 
The effect of antipsychotics on Dvl-3 and β-catenin 229 
No antipsychotic treatment showed significant effect on the protein expression of Dvl-3 230 
in either the NAc or CPu (NAc, F3, 20 = 1.170, p > 0.05; CPu, F3, 20 = 0.647, p > 0.05). 231 
However, β-catenin was significantly altered in both regions. In the NAc, antipsychotics 232 
significantly affected the expression of β-catenin (F3, 20 = 4.430, p < 0.05); while in the 233 
CPu, the levels of p-β-catenin were changed (NAc, F3, 20 = 5.698, p < 0.01). Post-hoc 234 
tests have indicated that in the NAc, both aripiprazole and risperidone significantly 235 
reduced the expression of β-catenin by 34.9% (p < 0.01) and 24.5% (p < 0.05), 236 
respectively (Figure 1(c), 1(d)); they also significantly elevated the ratio of p-β-catenin/β-237 
catenin (both p < 0.05) (Figure 1(c)). Olanzapine also tended to decrease the expression 238 
of β-catenin (p = 0.63, -20.6%) and increase the ratio of p-β-catenin/β-catenin in the NAc 239 
(p = 0.092). In the CPu, only risperidone was able to exert significant effects on the 240 
protein levels of p-β-catenin (+139.7%, p < 0.01) (Figure 2(c), 2(d)) as well as the ratio 241 
of p-β-catenin/β-catenin (p < 0.01) (Figure 2(c)). 242 
The effects of antipsychotics on PKA 243 
The protein levels of PKA-C (NAc, F3, 20 = 1.196, p > 0.05; CPu, F3, 20 = 0.158, p > 0.05) 244 
and p-PKA-C (Thr197) (F3, 20 = 0.409, p > 0.05; CPu, F3, 20 = 0.644, p > 0.05) were not 245 
significantly affected by any antipsychotic treatment in the two brain regions (Figure 246 
3(a), 3(d), 4(a), 4(d)). 247 
The effects of antipsychotics on CREB1 248 




NAc (CREB1, F3, 20 = 0.449, p > 0.05; p-CREB1, F3, 20 = 4.451, p < 0.05), but no change 250 
was found in the CPu (CREB1, F3, 20 = 0.088, p > 0.05; p-CREB1, F3, 20 = 1.439, p > 251 
0.05). Individual comparisons have shown that in the NAc, aripiprazole and risperidone 252 
significantly elevated the levels of p-CREB1 by 34.9% (p < 0.05) and 59.1% (p < 0.01), 253 
as well as the ratios of p-CREB1/CREB1 (both p < 0.01) (Figure 3(b), 3(d)). Moreover, 254 
the ratio of p-CREB1/CREB1 was shown to be positively correlated with the ratio of p-255 
GSK3β/GSK3β (p < 0.01, r = 0.493) (Figure 5(a)). 256 
The effects of antipsychotics on NMDA receptor subunits 257 
In the NAc, both NMDA NR1 and NR2A expression were significantly altered by 258 
antipsychotic treatment (NR1, F3, 20 = 5.099, p < 0.01; NR2A, F3, 20 = 10.903, p < 0.01). 259 
Post-hoc comparisons have indicated that all three antipsychotics up-regulated the protein 260 
expression of the NDMA NR1 subunit (aripiprazole, +35.0%, p < 0.05; olanzapine, 261 
+47.2%, p < 0.01; risperidone, +53.1%, p < 0.01); additionally, both aripiprazole and 262 
olanzapine significantly elevated the expression of the NMDA NR2A subunit 263 
(aripiprazole, +67.1%, p < 0.01; olanzapine, +106.2%, p < 0.01) (Figure 2(c), 2(d)). In 264 
the CPu, no drug was able to alter the expression of NMDA receptor subunits (NR1, F3, 20 265 
= 1.127, p > 0.05; NR2A, F3, 20 = 0.404, p > 0.05) (Figure 4(c), 4(d)). Furthermore, 266 
correlation tests have demonstrated that the expression of NMDA NR1 subunit was 267 
positively correlated with the phosphorylation ratio of β-catenin (p < 0.01, r = 0.705) and 268 
CREB1 (p < 0.01, r = 0.475) (Figure 5(b), 5(c)). 269 
The effect of antipsychotics on GABAA receptor 270 




antipsychotic administration (F3, 20 = 3.363, p < 0.05). Elevated expression of GABAA (β-272 
1) receptor induced by aripiprazole (+52.5%, p < 0.05) has been observed; additionally, 273 
risperidone tended to increase GABAA (β-1) receptor expression (p = 0.1, +37.4%) 274 
(Figure 3(c), 3(d)). In the CPu, GABAA (β-1) receptor was also significantly influenced 275 
by antipsychotic administration (F3, 20 = 9.732, p < 0.01), and its expression was 276 
promoted by the administration with both aripiprazole and olanzapine (aripiprazole, 277 
+90.0%, p < 0.01; olanzapine, +85.6%, p < 0.01) (Figure 4(c), 4(d)). 278 
Discussion 279 
The present study has examined the antipsychotic modulations on PKA- and GSK3β-280 
dependent signalling pathways, as well as NMDA and GABAA receptors, in the NAc and 281 
CPu of juvenile male rats. Our results indicated that aripiprazole, olanzapine, and 282 
risperidone differentially affected these signalling pathways and receptors; and their 283 
effects are also brain-regionally dependent (Table 1).  284 
Modulations of antipsychotics on the GSK3β-associated signalling pathways 285 
Abnormal GSK3β signalling has been reported in a number of mental disorders, 286 
including schizophrenia, autism, bipolar disorders, and depression (Hur and Zhou, 2010). 287 
The present study has revealed that all three antipsychotics were able to significantly 288 
increase the ratio of phosphorylated GSK3β in the NAc of the juvenile rats, indicating 289 
that the function of GSK3β in the juvenile rats was inhibited by these antipsychotic 290 
drugs. These findings are generally consistent with those of various previous studies in 291 
adult rats (Emamian et al., 2004; Alimohamad et al., 2005a; Alimohamad et al., 2005b; 292 




the effects of antipsychotics on adult rats have also shown that acute, short-term, and 294 
chronic administration with aripiprazole elevated the phosphorylation levels of GSK3β in 295 
the NAc (Pan et al., 2015; Pan et al., 2016a; Pan et al., 2016b). Taken together, it is very 296 
likely that antipsychotics (at least aripiprazole) modulate GSK3β activity in juvenile rats 297 
in a similar manner as in adults.  298 
A number of previous studies, including two studies from our group, have demonstrated 299 
that various classes of antipsychotics (e.g. aripiprazole, olanzapine, and risperidone) can 300 
increase the signalling of β-catenin in the striatum of adult animals (Alimohamad et al., 301 
2005b; Alimohamad et al., 2005a; Sutton and Rushlow, 2011; Seo et al., 2015; Pan et al., 302 
2016a; Pan et al., 2016b; Park et al., 2011). Consistent with these previous studies, the 303 
current study has also found up-regulation of the phosphorylation levels of β-catenin in 304 
the NAc of juvenile rats by all three antipsychotics (although the effect of olanzapine did 305 
not reach significance). Therefore, it could be concluded that β-catenin-mediated 306 
signalling in the NAc is very likely to be one of the major targets of antipsychotics in 307 
both youths and adults.  308 
Modulations of antipsychotics on CREB1 309 
Novel variants in the CREB1 gene have been identified in schizophrenic subjects 310 
(Kawanishi et al., 1999), and a number of in vivo studies reported that antipsychotics can 311 
increase the phosphorylation levels of CREB1 in adult animals (Pozzi et al., 2003; 312 
Konradi and Heckers, 1995; Mavrikaki et al., 2014; Pan et al., 2016c; Pan et al., 2016b; 313 
Rogoz et al., 2017; Einoch et al., 2017). CREB1 has also been found to be associated 314 




disorders (Burcescu et al., 2010). In the present study in juvenile rats, both aripiprazole 316 
and risperidone, but not olanzapine, significantly elevated the phosphorylation levels of 317 
CREB1 in the NAc. These data were consistent with those findings from adult animals or 318 
the neurons from adult animals, suggesting that in both juveniles and adults, 319 
antipsychotics react with CREB1 in similar patterns.  320 
It is interesting that similar to the influences of aripiprazole, risperidone, and olanzapine 321 
on the phosphorylation levels of GSK3β and β-catenin, aripiprazole and risperidone also 322 
induced larger alterations in the phosphorylation of CREB1 than that induced by 323 
olanzapine in the NAc. It has been reported that the affinity of aripiprazole and 324 
risperidone for D2Rs is higher than that of olanzapine (Correll, 2010). Therefore, the 325 
stronger influences induced by aripiprazole and risperidone on CREB1 is very likely to 326 
be caused by their higher affinity for D2Rs. However, the signalling pathway(s) through 327 
which D2Rs regulate CREB1 requires further exploration. 328 
It has been revealed that extensive communication occurs between CREB1 and GSK3β 329 
(Lonze and Ginty, 2002). Consistent with the findings of our previous study in adult rats 330 
(Pan et al., 2016b), the data of the present study revealed a positive correlation between 331 
the phosphorylation level of GSK3β and that of CREB1 in the NAc. The phenomenon 332 
that CREB1 activity can be enhanced by inhibition of GSK3β was observed in both in 333 
vitro and in vivo studies (Liang and Chuang, 2006; Park et al., 2011). Moreover, it has 334 
been revealed that patients with novel variants in the CREB1 gene experienced positive 335 
symptoms of schizophrenia (Kawanishi et al., 1999). Therefore, taken together, it is 336 
suggested that activation of CREB1 via inhibition of the function of GSK3β in the NAc is 337 




adults. Considering the extent of the alterations in GSK3β and CREB1 caused by these 339 
antipsychotics, it is also suggested that the activation of CREB1 via inhibiting GSK3β 340 
functions is likely to be associated with the levels of the binding affinity for D2Rs of 341 
antipsychotics. 342 
Antipsychotics might modulate NMDA receptor subunits via GSK3β-β-343 
catenin and/or CREB1 signalling 344 
It has been widely accepted that abnormal NMDAR neurotransmission is associated with 345 
many types of mental disorders, including schizophrenia, depression, bipolar disorder, 346 
and autism (Yamamoto et al., 2015). Previous studies showed that antipsychotic drug 347 
administration (e.g. clozapine and aripiprazole) elevated the NMDAR binding density 348 
and expression of protein and mRNA of NMDAR subunits in various brain regions of 349 
adult rats, including the NAc, hippocampus, and cortex (Pan et al., 2016b; Schmitt et al., 350 
2003). The present study demonstrated that both aripiprazole and olanzapine 351 
administration for 20 days were able to raise the expression levels of NMDA NR1 and 352 
NR2A subunits in the NAc of juvenile rats. Therefore, elevating NDMAR expression is 353 
very likely to be a shared action of antipsychotics in both juvenile and adult rats.  354 
It should be noted that antipsychotics do not directly bind with NMDARs. Thus, it is 355 
possible that antipsychotics modulate NMDARs via D2R-mediated signalling pathways. 356 
Previous evidence has revealed the association between GSK3β-β-catenin signalling and 357 
the activity of NMDARs (Saiepour et al., 2017; Singh et al., 2017; Wu et al., 2016; Wan 358 
et al., 2012; Mills et al., 2014; Sanges et al., 2013). In the current study, we found that the 359 




level of β-catenin in the NAc after antipsychotic treatment (Figure 5(c)). Thus, taken 361 
together with previous studies, our finding further proposes a potential regulation by 362 
antipsychotics of NMDARs via GSK3β-β-catenin signalling through the D2R (Figure 6).  363 
It is also worth noting that antipsychotics might regulate NMDARs via CREB1, as has 364 
been reported by several previous studies (Mavrikaki et al., 2014; Yuan et al., 2010; 365 
Snyder and Gao, 2013). The present study has shown that the NMDA NR1 expression 366 
was positively correlated with the CREB1 phosphorylation in the NAc, further 367 
confirming the relationship between CREB1 and NMDARs. Taken together with 368 
previous evidence (Lonze and Ginty, 2002), it has been suggested that antipsychotics 369 
might modulation NMDARs via PKA-CREB1 signalling (Figure 6). However, exact 370 
evidence is still required. 371 
Modulations of antipsychotics on the GABAA (β-1) receptor 372 
The GABAA receptor has also been widely reported to be involved in various mental 373 
disorders in children/adolescents, such as schizophrenia, depression, bipolar disorder, and 374 
autism (Rudolph and Mohler, 2014; Chiapponi et al., 2016), while antipsychotics can 375 
regulate GABAA receptors. For example, 1-week treatment with both haloperidol and 376 
olanzapine increased the binding density of GABAA receptors in the prefrontal cortex of 377 
adult rats (Skilbeck et al., 2007). A 6-month clozapine administration reduced the 378 
bindings of GABAA receptors in the anterior cingulate and infralimbic cortex of adult rats 379 
(Zink et al., 2004). Our previous studies have found that the expression of GABAA 380 
receptors was elevated by both 1-week and 10-week aripiprazole administration in the 381 




aripiprazole and olanzapine administration were able to elevate GABAA receptor 383 
expression, which were generally consistent with the results of previous studies (Skilbeck 384 
et al., 2007; Zink et al., 2004; Pan et al., 2016c; Pan et al., 2016b), suggesting that the 385 
modulation of antipsychotics (at least aripiprazole) on GABAA (β-1) receptors are similar 386 
in both youths and adults. 387 
Like NMDARs, although antipsychotics can impact GABAA receptors, they do not 388 
directly interact with these receptors. Previous studies pointed out that GABAA receptors 389 
can be regulated by the D2R-downstream PKA signalling pathway (Poisbeau et al., 1999; 390 
Connelly et al., 2013). Our previous studies revealed that 1-week antipsychotic treatment 391 
modulated both the PKA phosphorylation levels and the expression of GABAA receptors 392 
in the NAc (Pan et al., 2016c), whereas 10-week antipsychotic treatment affected 393 
GABAA receptor expression only (Pan et al., 2016b). The results of the current study in 394 
which animals were treated for 3 weeks were similar as those of the 10-week in vivo 395 
study in adult rats (Pan et al., 2016b). It seems that antipsychotics alter PKA in a time-396 
dependent manner (Figure 6), probably due to adaptive changes in dopamine D2 receptors 397 
after a relatively long period (more than 1 week) of treatment, which however needs 398 
further validation.  399 
The brain-regional differences of the modulations of antipsychotics 400 
In the present study, the antipsychotics had very limited affections in the CPu in 401 
comparison with those in the NAc, indicating brain-regional differences of the 402 
modulations of antipsychotics in juvenile rats. This phenomenon is generally consistent 403 




The exact reason for these differences in these two brain regions (NAc and CPu) remains 405 
unclear. It is possible that these differences might be caused by the heterogeneous 406 
structures of these brain regions that possess different neural inputs and outputs 407 
connected with various brain regions (Yager et al., 2015). For example, the NAc and CPu 408 
receive dopaminergic inputs from different brain areas – the ventral tegmental area and 409 
substantia nigra pars, respectively; in addition, outputs of NAc connect with the limbic 410 
areas and prefrontal cortex, while neurons in the CPu project to neocortical areas (Yager 411 
et al., 2015).  412 
Notes of intrinsic activity of the three antipsychotics for D2Rs 413 
In the present study, the three agents have different intrinsic activities for D2Rs. As a D2R 414 
partial agonist, the intrinsic activity of aripiprazole for D2R is lower than that of 415 
endogenous dopamine. Thus, when aripiprazole competes with endogenous dopamine to 416 
bind with D2Rs in normal animals, the overall activation of D2Rs could be weaker than 417 
that caused by endogenous dopamine solely, thereby showing antagonistic effects on 418 
D2Rs. Therefore, in the present study, aripiprazole displayed antagonistic effects on D2Rs 419 
as haloperidol.  420 
In our previous studies (Pan et al., 2016; Pan et al., 2016b; Pan et al., 2016c), we found 421 
that bifeprunox, a potent D2R partial agonist, also exerted certain antagonistic effects on 422 
D2Rs instead of agonistic effects in healthy animals. However, the intrinsic activity of 423 
bifeprunox is higher than that of aripiprazole, thereby, the observed antagonistic effects 424 






In conclusion, the present study investigated the modulations of aripiprazole, olanzapine, 428 
and risperidone on various signalling pathways in the NAc and CPu of juvenile rats, 429 
revealing that these antipsychotics share some common effects on these signalling 430 
pathways, but differential modulations of these antipsychotics also existed. Furthermore, 431 
this study found that NMDA and GABAA receptors can be modulated by these 432 
antipsychotics and revealed possible involvement of GSK3β-β-catenin and/or CREB1 433 
pathways in these modulations. Overall, in view of the involvement of NDMA and 434 
GABAA receptors in the pathophysiology of various mental disorders, this study suggests 435 
that antipsychotics might exert their therapeutic effects in treating mental disorders by 436 
modulating NMDA and GABAA receptors via PKA- and GSK3β-dependent signalling 437 
pathways in childhood-adolescence. The current study has provided in vivo evidence at 438 
the molecular level that could be a reference for clinical prescription of childhood 439 
schizophrenia, further studies, however, are still necessary by using juvenile animal 440 
disease models (such as bipolar disorder, autism, schizophrenia, etc.) to investigate how 441 
antipsychotics impact behaviours and reverse deficits of animals via these signalling 442 
pathways, as well as to examine direct regulations of antipsychotics on genes and protein 443 
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Figure 1. Effects of three antipsychotics on Akt, GSK3β, Dvl-3 and β-catenin in the 661 
nucleus accumbens. The effects of aripiprazole (ARI), olanzapine (OLA) and 662 
risperidone (RIS) on Akt (a), GSK3β (b), Dvl-3 and β-catenin (c) were measured in the 663 
nucleus accumbens. The representative bands of Western blot are shown in (d). Akt was 664 
quantified at 60kDa; p-Akt (Thr308) was quantified at 60kDa; GSK3β was quantified at 665 
46kDa; p-GSK3β (Ser9) was quantified at 46kDa; Dvl-3 was quantified at 85kDa; β-666 
catenin was quantified at 92kDa; p-β-catenin was quantified at 92kDa. The data were 667 
normalised by taking the average value of the control group as 100% and expressed as 668 





Figure 2. Effects of three antipsychotics on Akt, GSK3β, Dvl-3 and β-catenin in the 671 
caudate putamen. The effects of aripiprazole (ARI), olanzapine (OLA) and risperidone 672 
(RIS) on Akt (a), GSK3β (b), Dvl-3 and β-catenin (c) were measured in the caudate 673 
putamen. The representative bands of Western blot are shown in (d). Akt was quantified 674 
at 60kDa; p-Akt (Thr308) was quantified at 60kDa; GSK3β was quantified at 46kDa; p-675 
GSK3β (Ser9) was quantified at 46kDa; Dvl-3 was quantified at 85kDa; β-catenin was 676 
quantified at 92kDa; p-β-catenin was quantified at 92kDa. The data were normalised by 677 
taking the average value of the control group as 100% and expressed as mean ± S.E.M. (* 678 





Figure 3. Effects of three antipsychotics on PKA-C, CREB1, NMDA NR1, NR2A 681 
and GABAA β-1 receptors in the nucleus accumbens. The effects of aripiprazole 682 
(ARI), olanzapine (OLA) and risperidone (RIS) on PKA-C (a), CREB1 (b), NMDA NR1 683 
and NR2A (c) and GABAA β-1 receptor (c) were measured in the nucleus accumbens. 684 
The representative bands of Western blot are shown in (d). PKA-C was quantified at 685 
42kDa; p-PKA-C (Thr197) was quantified at 42kDa; CREB1 was quantified at 40kDa; p-686 
CREB1 was quantified at 37kDa; NMDA NR1 subunit was quantified at 105kDa; NMDA 687 
NR2A subunit was quantified at 165kDa; and GABAA β-1 receptors were quantified at 688 
54kDa. The data were normalised by taking the average value of the control group as 689 





Figure 4. Effects of three antipsychotics on PKA-C, CREB1, NMDA NR1, NR2A 692 
and GABAA β-1 receptors in the caudate putamen. The effects of aripiprazole (ARI), 693 
olanzapine (OLA) and risperidone (RIS) on PKA-C (a), CREB1 (b), NMDA NR1 and 694 
NR2A (c) and GABAA β-1 receptor (c) were measured in the caudate putamen. The 695 
representative bands of Western blot are shown in (d). PKA-C was quantified at 42kDa; 696 
p-PKA-C (Thr197) was quantified at 42kDa; CREB1 was quantified at 40kDa; p-CREB1 697 
was quantified at 37kDa; NMDA NR1 subunit was quantified at 105kDa; NMDA NR2A 698 
subunit was quantified at 165kDa; and GABAA β-1 receptors were quantified at 54kDa. 699 
The data were normalised by taking the average value of the control group as 100% and 700 





Figure 5. Correlations between the ratio of p-GSK3β/GSK3β and the ratio of p-703 
CREB1/CREB1, the ratio of p-β-catenin/β-catenin and the expression of NMDA 704 
NR1 subunit, and the ratio of p-CREB1/CREB1 and the expression of NMDA NR1 705 
subunit in the nucleus accumbens. The ratio of p-CREB1/CREB1 was positively 706 
correlated with the ratio of p-GSK3β/GSK3β (a); the expression of NMDA NR1 subunit 707 
was positively correlated with the ratio of p-β-catenin/β-catenin (b), as well as the ratio of 708 







Figure 6. A proposed schematic diagram illustrating the possible signalling 713 
pathways through which antipsychotics affect NMDA and GABAA receptors in the 714 
nucleus accumbens. Antipsychotics bind with the dopamine D2-like receptor, probably 715 
resulting in the phosphorylation of GSK3β and β-catenin, which finally induces the 716 
elevation in the expression of NMDA receptor subunits (a). Reaction with D2-like 717 
receptors by antipsychotics results in the increase in the expression of NMDA receptors 718 
probably via the PKA-CREB1 signalling pathway (b). Antipsychotics might modulate 719 
GABAA receptors via PKA signalling in juveniles in a time-dependent manner (c). (The 720 
dashed arrows indicate our speculative ideas.) 721 
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